It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Two drug companies, Genentech and OSI Pharmaceuticals, have agreed to pay $67 million to settle a whistleblower lawsuit accusing them of misleading doctors about the effectiveness of a cancer drug called Tarceva. – By agreeing to the settlement, neither company admitted any guilt.
.
. . .
.
Shields alleged that the company had provided doctors and medical professionals with misleading information about Tarceva. According to a news release received by CNN, the companies had led doctors to believe that the drug would be effective in a broad patient population.
.
But Genentech and OSI knew there was little evidence to support that claim, and that Tarceva had been shown to be effective only in non-small-cell lung cancer patients who had never smoked, or who had a particular genetic mutation in the epidermal growth factor receptor (EGFR), which is involved with cancer growth. The lawsuit alleged also that the companies’ promotional materials discouraged testing for EGFR mutation.
.
Read more: naturalsociety.com...
Follow us: @naturalsociety on Twitter | NaturalSociety on Facebook
.
. . .
.
Two drug companies, Genentech and OSI Pharmaceuticals, have agreed to pay $67 million to settle a whistleblower lawsuit accusing them of misleading doctors about the effectiveness of a cancer drug called Tarceva. – By agreeing to the settlement, neither company admitted any guilt.